Drug Profile

AGMB 447

Alternative Names: AGMB-447; ORG-447

Latest Information Update: 09 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Origo Biopharma
Developer AgomAb Therapeutics
Class Antifibrotics; Small molecules
Mechanism of Action Transforming growth factor beta type I receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Idiopathic pulmonary fibrosis
New Molecular Entity Yes

Highest Development Phases

Phase I Idiopathic pulmonary fibrosis

Most Recent Events

29 Apr 2026 Agomab Therapeutics completes a phase I trial for Idiopathic pulmonary fibrosis in the United Kingdom (NCT06181370)
27 Apr 2026 MHRA recommends positive scientific advice for planned phase II trial in Idiopathic pulmonary fibrosis
26 Mar 2026 The United States Patent and Trademark Office (USPTO) has granted US Patent for AGMB 447

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com